Shots:

• Curacle to receive a total of ~$2B including $6M up front & is eligible to receive ~$157.5M as development, regulatory and sales milestones along with royalties on sales upon the successful development of CU06-RE. The companies will closely collaborate on the clinical development of the product
• Curacle will hold the marketing rights in all Asia countries & will lead the P-I & II clinical studies with TOI to provide both financial and infrastructure support while Théa will get the marketing rights in all other countries globally
• The focus of the collaboration is to provide a new treatment with an alternative and non-invasive RoA for patients

 ­  Ref: Businesswire | Image: Businesswire